UroGen Pharma Ltd. Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
UroGen Pharma Ltd. (URGN) reported Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $19.50 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2026-03-02
- UroGen Pharma Ltd. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2025 was $19.50.
- UroGen Pharma Ltd. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2023 was $17.94, a 51.01% increase from fiscal 2022.
- UroGen Pharma Ltd. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2022 was $11.88, a 46.17% decline from fiscal 2021.
- UroGen Pharma Ltd. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2021 was $22.07, a 24.96% decline from fiscal 2020.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month |
|---|---|---|
| 2025-12-31 | $19.50 10-K · filed 2026-03-02 | |
| 2024-12-31 | $15.16 10-K · filed 2025-03-10 | |
| 2023-12-31 | $17.94 10-K · filed 2024-03-14 | |
| 2022-12-31 | $11.88 10-K · filed 2024-03-14 | |
| 2021-12-31 | $22.07 10-K · filed 2023-03-24 | |
| 2020-12-31 | $29.41 10-K · filed 2022-03-21 | |
| 2019-12-31 | $47.57 10-K · filed 2021-03-18 | |
| 2018-12-31 | $59.23 10-K · filed 2020-03-02 | |
| 2017-12-31 | $39.26 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |